Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Breast Cancer Clinical Trials

Study of Patients With Male Breast Cancer Treated Within the Past 20 Years (7342)
Clinical and Biological Characterization of Male Breast Cancer: An International Retrospective EORTC, BIG and NABCG Intergroup Study
Status Conditions Phase Study ID
Closed Male Breast Cancer N/A 7342
NCT01101425
Summary

This clinical trial will study medical charts and tumor samples from patients with male breast cancer treated within the past 20 years.

This is a multicenter study. Patients are stratified according to disease extent (metastatic vs non-metastatic).

 

Patient charts will be reviewed and data entered into a database. Data will be collected on patient epidemiology (e.g., age, ethnicity), possible risk factors (e.g., family history of cancer, chronic liver disease, obesity), and tumor characteristics (e.g., pathologic size, lymph node involvement, stage of disease, tumor grade, ER and PgR status, HER2 over-expression and results of BRCA 1 and 2 testing). Information regarding surgical therapy, radiotherapy, chemotherapy, and endocrine therapy will be collected. Patient outcomes, (e.g., disease recurrence or progression, new primary cancer, and overall survival) will be noted.

Tumor blocks must be collected and sent to central laboratories in United States (US samples) and in United Kingdom (Europe and the rest of the world samples) for central pathology assessment of several biomarkers in formalin-fixed, paraffin-embedded tissue. Fresh frozen tumor samples, when available, will be requested and analyzed in laboratories in Netherlands and US.

 


Investigator
Larissa Korde, MD
Location    
SCCA Breast Cancer Clinical Trials Program 800-804-8824 Refer Patient
Eligibility Criteria (must meet the following to participate in this study)
  • Histologically confirmed invasive breast carcinoma diagnosed since 1990 to present date

    • Stage I-IV or recurrent disease (e.g., early, locally advanced, or metastatic disease)
  • Concomitant ductal carcinoma in situ (CIS) or lobular CIS are allowed if invasive cancer is present
  • Must have a formalin-fixed, paraffin-embedded tissue sample from primary tumor (e.g., biopsy or surgery)
Last Updated
January 22, 2013
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.